[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]  Ryan sikorski [@Ryansikorski10](/creator/twitter/Ryansikorski10) on x 35.2K followers Created: 2025-04-28 23:10:36 UTC Ginkgo Bioworks alongside partners Tritica Demand and Isolere Bio by Donaldson are awarded a $XX million contract by ARPA-H for the two-year program, Wheat-based High efficiency Enzyme and API Technology (WHEAT). WHEAT aims to establish a new manufacturing process for the distributed production of biologic and small molecule active pharmaceutical ingredients (APIs) using wheat germ cell-free expression systems. Ginkgo will combine its Enzyme Services and expertise in cell-free systems with the expertise and experience of its partners in upstream extract preparation, API downstream processing, quality metrics, and modular, on-demand API manufacturing methods, with the aim of developing affordable cell-free biological processes to produce essential medicines. By utilizing wheat germ - an abundant and renewable resource - and developing methods to produce medicines exactly where and when they are needed, the partnership seeks to create a new paradigm for domestic manufacturing of critical medicines, stabilizing and reshoring supply chains for essential pharmaceuticals. This strategy shifts API production from fragile global supply chains to a robust, decentralized system using Cell-Free Protein Synthesis (CFPS). WHEAT aims to demonstrate scalable and decentralized processes for CFPS-based production of complex APIs, focusing on targets where biocatalysis can wholly or partially complete syntheses, and where current supply chains are constrained to natural products or overseas providers. Additionally, WHEAT's innovations in protein post-translational modifications (PTMs) aim to establish a foundation suitable for production of biologics such as growth factors and insulin, offering a broader range of applications and establishing a foundation for further expanding the potential of CFPS to even more complex products.  XXX engagements  **Related Topics** [stocks technology](/topic/stocks-technology) [dna ginkgo bioworks holdings](/topic/dna-ginkgo-bioworks-holdings) [Post Link](https://x.com/Ryansikorski10/status/1916993481790173428)
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
Ryan sikorski @Ryansikorski10 on x 35.2K followers
Created: 2025-04-28 23:10:36 UTC
Ginkgo Bioworks alongside partners Tritica Demand and Isolere Bio by Donaldson are awarded a $XX million contract by ARPA-H for the two-year program, Wheat-based High efficiency Enzyme and API Technology (WHEAT). WHEAT aims to establish a new manufacturing process for the distributed production of biologic and small molecule active pharmaceutical ingredients (APIs) using wheat germ cell-free expression systems.
Ginkgo will combine its Enzyme Services and expertise in cell-free systems with the expertise and experience of its partners in upstream extract preparation, API downstream processing, quality metrics, and modular, on-demand API manufacturing methods, with the aim of developing affordable cell-free biological processes to produce essential medicines. By utilizing wheat germ - an abundant and renewable resource - and developing methods to produce medicines exactly where and when they are needed, the partnership seeks to create a new paradigm for domestic manufacturing of critical medicines, stabilizing and reshoring supply chains for essential pharmaceuticals. This strategy shifts API production from fragile global supply chains to a robust, decentralized system using Cell-Free Protein Synthesis (CFPS).
WHEAT aims to demonstrate scalable and decentralized processes for CFPS-based production of complex APIs, focusing on targets where biocatalysis can wholly or partially complete syntheses, and where current supply chains are constrained to natural products or overseas providers. Additionally, WHEAT's innovations in protein post-translational modifications (PTMs) aim to establish a foundation suitable for production of biologics such as growth factors and insulin, offering a broader range of applications and establishing a foundation for further expanding the potential of CFPS to even more complex products.
XXX engagements
Related Topics stocks technology dna ginkgo bioworks holdings